After the completion of bridging CDCT, most (61.5%) required both tumor markers (AFP, BHCG, LDH) and radiological imaging to assess the response; 69.2% of those would have patients proceed to HDCT and ASCT regardless of the biochemical and radiology response. This evidence concerns the gene AFP and neoplasm.